04Mar 2023
AMPK Activation: Respiratory Panacea?

AMPK Activation: Respiratory Panacea?

The article discusses bronchopulmonary dysplasia (BPD), a chronic lung disease that affects about 35% of US newborns with extremely low gestational age. The development of the gas exchange apparatus in the lung during late lung development can be disrupted in preterm infants, leading to BPD. The role of inflammation in BPD pathogenesis is strongly supported, but the exact pathophysiology remains unclear. The study by Soni and colleagues focuses on the effect of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), a direct AMP-activated protein kinase (AMPK) activator, in a murine hyperoxic model of BPD with a focus on the role of autophagy in AMPK-induced macrophage responses. The results show that AICAR treatment resulted in reduced alveolar simplification and increased density of myofibroblasts in the lung, along with decreased expression of proinflammatory and increased expression of proreparative genes in alveolar macrophages. The article highlights a novel role for autophagy in lung macrophage maturation during lung development. AMPK activation has been associated with favorable metrics in BPD models in the past.

  • #pulmonology

Like

Save

Share